Ik interpreteer dit als: Mithra heeft alle rechten op E4, maar hebben de onderzoeken/licenties ivm kankers uitbesteed aan Pantarhei.
Mithra Pharmaceuticals acquires full rights to Estetrol (E4) from Pantarhei Bioscience
4 April 2015
Two months after acquiring the rights to Estetrol in the field of oral contraceptives and the recent capital inflow from M. Coucke, Mithra Pharmaceuticals is once again consolidating its innovation portfolio, this time by acquiring full rights to Estetrol from Pantarhei Bioscience. This agent offers therapeutic prospects perfectly in keeping with the four main spheres of gynaecology covered by Mithra Pharmaceuticals.
“Mithra is a pharmaceutical company focused on women’s health. Through our products and Research & Development projects, we cover the four major spheres of gynaecology, namely fertility and contraception, the menopause and osteoporosis, gynaecological infections, and also cancer. The acquisition of Donesta gives us the opportunity to operate several patents in three of our four therapeutic areas. This is major progress in our company’s position,” explains François Fornieri, CEO of Mithra Pharmaceuticals.
Pantarhei Bioscience will receive an initial payment, together with milestones based on the successful development of projects relating to the menopause.
Mithra Pharmaceuticals will grant Pantarhei Bioscience a licence for the development of human applications in oncology and veterinary applications. The Dutch firm will study therapies for reproductive organ cancers, such as ovarian cancer and breast cancer. Mithra will have the right to first refusal should Pantarhei Bioscience undertake partnership negotiations.
Professor Herjan Coelingh Bennink, CEO of Pantarhei Bioscience, will be on the board of Mithra Pharmaceuticals and will become Co-Chairman of the scientific committee.
“We are delighted about this acquisition which has given Mithra Pharmaceuticals additional essential assets. Mithra intends to focus initially on the applications relating to contraception and the menopause, two essential and extremely dynamic markets,” declares François Fornieri, CEO of Mithra Pharmaceuticals.